Objectives Smoking is recognised as one of the strongest environmental risk factors for the development of rheumatoid ...

Objectives Owing to the underrepresentation of early-stage disease in randomised trials and inconsistent clinical evidence, ...

Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence suggests that biologic therapies may differentially influence the development ...

Over the last decade, the outlook for patients with rheumatoid arthritis (RA) has improved, but there is growing interest in ...

What is already known on this topic Low-dose glucocorticoids (≤7.5 mg/day prednisone equivalent) are frequently used as a long-term cotreatment for rheumatoid arthritis in real-world settings. Trials ...

Background Involvement of hands is a frequent finding in polymyalgia rheumatica (PMR) and can lead to misclassification as late-onset rheumatoid arthritis (RA). Objective To compare the inflammatory ...

Objective Paradoxical arthritis under tumour necrosis factor inhibitor (TNF-i) for inflammatory bowel disease (IBD) has been described. This study aims to evaluate the histological features of paired ...

Multicentric reticulohistiocytosis (MRH) is a rare non-Langerhans cell histiocytosis characterised by erosive arthritis and papulonodular skin lesions, frequently associated with autoimmune features.

Objectives Nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, has been extensively investigated for the treatment of pulmonary fibrosis; however, its therapeutic potential and ...

Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) ...

Objective Axial spondyloarthritis (axSpA) comprises both radiographic and non-radiographic disease. However, the paucity of specific objective measures for the disease and current classification ...